Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 8Active not recruiting 4Completed 3Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Glioma 1Ependymoma 1Choroid Plexus Carcinoma 1Brain Neoplasms 1

Interventions

Cytarabine 25Azacitidine 17fludarabine phosphate 15fludarabine 15Cyclophosphamide 14venetoclax 8Peripheral Blood Stem Cell Transplantation 8Methotrexate 8Busulfan 8Granulocyte Colony-Stimulating Factor 7Filgrastim 7Whole-Body Irradiation 6Decitabine 6Cyclosporine 6Injections 5Idarubicin 5decitabine and cedazuridine drug combination 4Tacrolimus 4Radiotherapy 4Mycophenolic Acid 4Mitoxantrone 4Daunorubicin 4Cladribine 4CPX-351 4Biopsy 4midostaurin 3merphos 3magrolimab 3gilteritinib 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Myeloid, Acute × Hematopoietic Stem Cell Transplantation × Clear all
NCT03881735 2021-03-10

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Roswell Park Cancer Institute

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡